- Home
- CIX vs DMAC Comparison
CIX vs DMAC Comparison
Compare CIX & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIX
- DMAC
- Stock Information
- Founded
- CIX 1993
- DMAC 2000
- Country
- CIX United States
- DMAC United States
- Employees
- CIX N/A
- DMAC N/A
- Industry
- CIX Industrial Machinery/Components
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CIX Consumer Discretionary
- DMAC Health Care
- Exchange
- CIX Nasdaq
- DMAC Nasdaq
- Market Cap
- CIX 301.8M
- DMAC 178.0M
- IPO Year
- CIX 1998
- DMAC N/A
- Fundamental
- Price
- CIX $26.90
- DMAC $3.76
- Analyst Decision
- CIX
- DMAC Strong Buy
- Analyst Count
- CIX 0
- DMAC 2
- Target Price
- CIX N/A
- DMAC $8.00
- AVG Volume (30 Days)
- CIX 6.7K
- DMAC 307.4K
- Earning Date
- CIX 08-05-2025
- DMAC 08-06-2025
- Dividend Yield
- CIX 4.55%
- DMAC N/A
- EPS Growth
- CIX N/A
- DMAC N/A
- EPS
- CIX 1.46
- DMAC N/A
- Revenue
- CIX $148,242,000.00
- DMAC N/A
- Revenue This Year
- CIX N/A
- DMAC N/A
- Revenue Next Year
- CIX N/A
- DMAC N/A
- P/E Ratio
- CIX $18.10
- DMAC N/A
- Revenue Growth
- CIX N/A
- DMAC N/A
- 52 Week Low
- CIX $17.89
- DMAC $2.80
- 52 Week High
- CIX $36.10
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- CIX 56.89
- DMAC 47.18
- Support Level
- CIX $22.81
- DMAC $3.48
- Resistance Level
- CIX $27.01
- DMAC $3.99
- Average True Range (ATR)
- CIX 1.12
- DMAC 0.32
- MACD
- CIX 0.21
- DMAC -0.00
- Stochastic Oscillator
- CIX 67.55
- DMAC 41.01
About CIX CompX International Inc.
Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's operating segment includes Security Products and Marine Components. The company generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Its geographical segments are the United States, Canada, Mexico, and others, of which the United States accounts for the vast majority of revenue.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.